Search
Totrombopag
go.drugbank.com/drugs/DB05930Investigationalused to treat Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of many chemotherapies and can lead to uncontrolled bleeding, thus representing a significant problem in
OSI-461
go.drugbank.com/drugs/DB05415InvestigationalOSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).
NCX 701
go.drugbank.com/drugs/DB05409ExperimentalNitroparacetamol (NCX-701) is a newly synthesized nitric oxide-releasing derivative of paracetamol.
Cilobradine
go.drugbank.com/drugs/DB20039InvestigationalCilobradine is under investigation in clinical trial NCT02264041 (Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine). … The usage of the INN stem '-bradine' in the name indicates that Cilobradine is a bradycardic agent.
Resomelagon
go.drugbank.com/drugs/DB21579InvestigationalResomelagon is under investigation in clinical trial NCT06917001 (Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)). … The usage of the INN stem '-melagon' in the name indicates that Resomelagon is a non-peptidic melanocortin receptor agonist.
Edonerpic
go.drugbank.com/drugs/DB05938InvestigationalEdonerpic is a neurotrophic agent intended for the treatment of Alzheimer's disease which is under phase I clinical trial.
KD3010
go.drugbank.com/drugs/DB05188ExperimentalKD3010 is a small molecule peroxisome proliferator-activator receptor delta (PPAR Delta) agonist for the treatment of metabolic disorders, including obesity.
Rasburicase
go.drugbank.com/drugs/DB00049ApprovedInvestigationalRasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.
Products: FASTURTEC®1.5 MG / ML, FASTURTEC POWDER FOR SOLUTION FOR INFUSION 1.5 mg/vialCX-2009
go.drugbank.com/drugs/DB16090InvestigationalCX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors).